Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux
- Registration Number
- NCT00392002
- Lead Sponsor
- AstraZeneca
- Brief Summary
To characterize the burden of disease in GERD patients of prescription therapy'
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- Signed informed consent, 18 years or older, diagnosis of GERD
Exclusion Criteria
- Peptic ulcer disease, upper gastrointestinal surgery, malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method To compare the improvement in burden of overall GERD symptoms after 4 weeks of treatment with Esomeprazole verses maintenance of current therapy in subjects with persistent GERD symptoms.
- Secondary Outcome Measures
Name Time Method To examine the relationship of the severity and frequency of GERD symptoms to treatment, at national, and regional levels.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PPI acid suppression in GERD patients as studied in NCT00392002?
How does the PASS test compare to endoscopy in predicting GERD treatment outcomes in the EncomPASS trial?
Are there specific biomarkers associated with PPI response in GERD patients from the EncomPASS study?
What are the long-term adverse events of PPI therapy in GERD management as observed in NCT00392002?
How does AstraZeneca's PPI approach in EncomPASS align with other GERD treatments like H2 receptor antagonists?
Trial Locations
- Locations (1)
Research Site
🇨🇦Toronto, Ontario, Canada
Research Site🇨🇦Toronto, Ontario, Canada